{"id":"W2598622099","doi":"10.1111/jdv.14237","title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>‐1, <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3)","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Celgene; Regeneron Pharmaceuticals; Novartis; Amgen; Pfizer; Allergan; Biogen Idec; Eli Lilly and Company; AbbVie; Merck","keywords":"Ixekizumab; Medicine; Placebo; Etanercept; Psoriasis; Palmoplantar pustulosis; Psoriasis Area and Severity Index; Internal medicine; Plaque psoriasis; Dermatology; Gastroenterology; Psoriatic arthritis; Pathology; Tumor necrosis factor alpha; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001645472,0.0006872506,0.002344747,0.000471138,0.0005668637,0.00006135667,0.0008780137,0.000687952,0.000005950862],"category_scores_gemma":[0.002659512,0.0004928814,0.0001963053,0.0001837149,0.0009066413,0.0003622267,0.0007320133,0.0008868803,0.00001849193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005227894,"about_ca_system_score_gemma":0.0001227674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001105963,"about_ca_topic_score_gemma":0.0001315371,"domain_scores_codex":[0.9939576,0.002465828,0.00185946,0.0007790777,0.000205722,0.0007323007],"domain_scores_gemma":[0.9922897,0.004135966,0.002615319,0.0005494048,0.0001619273,0.0002476561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01391111,0.001178425,0.9403344,0.0001972575,0.003728939,0.0003069489,0.007651739,0.0004934778,0.01172868,0.000130472,0.01499836,0.00534024],"study_design_scores_gemma":[0.08100983,0.001102116,0.8793108,0.0006537776,0.001520251,0.001202389,0.0009270986,0.00004556319,0.02471411,0.0006292511,0.008661532,0.0002232947],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993407,0.003171994,0.00007142608,0.0004690878,0.0005987521,0.0009433317,0.000791922,0.00001493043,0.0005316229],"genre_scores_gemma":[0.9975121,0.001261267,0.0003507039,0.0004228102,0.0001207718,0.00001052221,0.00008177864,0.00005525052,0.0001847878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06709872,"threshold_uncertainty_score":0.9997523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02923797173096592,"score_gpt":0.2649287669594539,"score_spread":0.235690795228488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}